Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Encephalitis ll: Pathophysiology

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Encephalitis l: Introduction

Encephalitis l: Introduction

Encephalitis is inflammation of the brain parenchyma, most often due to infections or autoimmune processes. It presents with neuropsychiatric features such as fever, altered mental status, behavioral changes, cognitive dysfunction, seizures, focal deficits, and sometimes autonomic instability. In some cases, the meninges are also involved, resulting in meningoencephalitis.Infectious CausesInfectious encephalitis is most commonly viral but can also result from bacterial, fungal, or parasitic...

Cerebral Edema ll: Pathophysiology

Cerebral Edema ll: Pathophysiology

Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this barrier loses...

Hepatic Encephalopathy

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...

Cerebral Edema l: Introduction

Cerebral Edema l: Introduction

Cerebral edema is a pathological increase in brain water content that disrupts intracranial pressure regulation and impairs neurological function. Because the cranial vault is rigid, even modest increases in tissue volume can compromise cerebral perfusion, distort neural structures, and initiate secondary injury. Cerebral edema develops through four principal mechanisms: vasogenic, cytotoxic, interstitial, and ionic.Vasogenic EdemaVasogenic edema arises from disruption of the blood–brain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Aortic valve closure associated with HeartMate left ventricular device support: technical considerations and long-term results.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2011

Same author

HeartMate left ventricular assist system exchange: results and technical considerations.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2009

Same author

Cardiac transplantation: candidate identification, evaluation, and management.

Critical care nursing quarterly·2008

Same author

Student Table Clinics at the MDA's Star of the North Meeting.

Northwest dentistry·2005

Same author

A NotI-EcoRV promoter library for studies of genetic and epigenetic alterations in mouse models of human malignancies.

Genomics·2004

Search research articles

Related Experiment Video

Updated: Jul 13, 2026

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

Progressive multifocal leukoencephalopathy: a case study.

Vicki McCalmont¹, Kristi Bennett

¹Sharp Memorial Hospital, San Diego, CA, USA.

Progress in Transplantation (Aliso Viejo, Calif.)

|July 13, 2007

Summary

Progressive multifocal leukoencephalopathy (PML) is a fatal brain infection. A case study found JC virus in a heart transplant patient on sirolimus, a drug previously not linked to PML.

Area of Science:

Neurology
Infectious Diseases
Immunology

Background:

Progressive multifocal leukoencephalopathy (PML) is a rare, fatal demyelinating brain infection caused by the JC virus.
PML is associated with immunosuppressive agents and is increasingly observed in transplant recipients.

Observation:

This study reports the first documented case of PML in a heart transplant recipient receiving sirolimus for immunosuppression.
The patient, a 68-year-old male, developed PML three years after an orthotopic heart transplant while on sirolimus and prednisone therapy.

Findings:

JC virus was detected in the patient, confirming PML.
This case challenges the established understanding of PML risk factors in immunosuppressed patients.

Implications:

More Related Videos

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

Published on: May 11, 2022

Related Experiment Videos

Last Updated: Jul 13, 2026

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

Published on: May 11, 2022

The findings suggest that sirolimus, in combination with other immunosuppressants, may be associated with PML development.
Further research is needed to elucidate the specific risks and mechanisms of PML in patients receiving sirolimus-based immunosuppression.
This case highlights the importance of vigilance for opportunistic infections like PML in transplant recipients, even when on seemingly lower-risk immunosuppressive agents.